NCT06723002Not yet recruitingPhase 2/3
Effect of Olive Leaf Extracts on Endothelial Dysfunction in Patients With Acute Coronary Syndrome
Effect of Olive Leaf Extracts on Endothelial Dysfunction and Short-term Outcome in Patients With Acute Coronary Syndrome
Source: ClinicalTrials.gov · Last updated 9 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
the study aims to examine the short-term (30 days) effects of olive leaf extract on endothelial function in patients with acute coronary syndrome (ACS). This investigation will be conducted on patients admitted to the emergency department for ACS. All participants will be screened and included within 24 hours post-ACS event and prior to discharge from the emergency department.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- First submitted
- 20 Nov 2024
- Start date
- 1 Dec 2024
- Primary completion date
- 30 Dec 2025
- Lead sponsor
- University of Monastir
- Diseases
- Coronary artery disease
- NCT number
- NCT06723002
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 300
- From 1 Dec 2024 to the primary completion date, 30 Dec 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients undergoing surgery within 30 days
Other illness
- Patients with any evidence of inflammatory or malignant disease.
- Patient having valvular heart disease, pacemaker; cardiogenic shock
- Patient having any serious non-cardiac disease associated with a life expectancy \<1 year
- Patient having gastrointestinal disorder such as Crohn's disease
Other
- Severe LV hypertrophy (\>15 mm);
Who the study is looking for
- Age over 18 years. Patients presenting with ST-segment alterations at rest, including ST elevation, with or without troponin elevation.
- Patients who have not undergone surgery or have no additional primary percutaneous coronary intervention (P-PCI) planned within 8 weeks from the initial P-PCI.
- Patients who provide informed consent. Patients available for and willing to adhere to follow-up procedures. Patients without significant cognitive impairment. Patients with a life expectancy of at least 2 years.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.